BACKGROUND AND PURPOSE: Although plasma total homocysteine (tHcy) levels are associated with cardiovascular disease, it remains unclear whether homocysteine is a cause or a marker of atherosclerotic vascular disease. We determined whether reduction of tHcy levels with B vitamin supplementation reduces subclinical atherosclerosis progression. METHODS: In this double-blind clinical trial, 506 participants 40 to 89 years of age with an initial tHcy >8.5 micromol/L without diabetes and cardiovascular disease were randomized to high-dose B vitamin supplementation (5 mg folic acid+0.4 mg vitamin B(12)+50 mg vitamin B(6)) or matching placebo for 3.1 years. Subclinical atherosclerosis progression across 3 vascular beds was assessed using high-resolution B-mode ultrasonography to measure carotid artery intima media thickness (primary outcome) and multidetector spiral CT to measure aortic and coronary artery calcium (secondary outcome). RESULTS: Although the overall carotid artery intima media thickness progression rate was lower with B vitamin supplementation than with placebo, statistically significant between-group differences were not found (P=0.31). However, among subjects with baseline tHcy >or=9.1 micromol/L, those randomized to B vitamin supplementation had a statistically significant lower average rate of carotid artery intima media thickness progression compared with placebo (P=0.02); among subjects with a baseline tHcy <9.1 micromol/L, there was no significant treatment effect (probability value for treatment interaction=0.02). B vitamin supplementation had no effect on progression of aortic or coronary artery calcification overall or within subgroups. CONCLUSIONS:High-dose B vitamin supplementation significantly reduces progression of early-stage subclinical atherosclerosis (carotid artery intima media thickness) in well-nourished healthy B vitamin "replete" individuals at low risk for cardiovascular disease with a fasting tHcy >or=9.1 micromol/L.
RCT Entities:
BACKGROUND AND PURPOSE: Although plasma total homocysteine (tHcy) levels are associated with cardiovascular disease, it remains unclear whether homocysteine is a cause or a marker of atherosclerotic vascular disease. We determined whether reduction of tHcy levels with B vitamin supplementation reduces subclinical atherosclerosis progression. METHODS: In this double-blind clinical trial, 506 participants 40 to 89 years of age with an initial tHcy >8.5 micromol/L without diabetes and cardiovascular disease were randomized to high-dose B vitamin supplementation (5 mg folic acid+0.4 mg vitamin B(12)+50 mg vitamin B(6)) or matching placebo for 3.1 years. Subclinical atherosclerosis progression across 3 vascular beds was assessed using high-resolution B-mode ultrasonography to measure carotid artery intima media thickness (primary outcome) and multidetector spiral CT to measure aortic and coronary artery calcium (secondary outcome). RESULTS: Although the overall carotid artery intima media thickness progression rate was lower with B vitamin supplementation than with placebo, statistically significant between-group differences were not found (P=0.31). However, among subjects with baseline tHcy >or=9.1 micromol/L, those randomized to B vitamin supplementation had a statistically significant lower average rate of carotid artery intima media thickness progression compared with placebo (P=0.02); among subjects with a baseline tHcy <9.1 micromol/L, there was no significant treatment effect (probability value for treatment interaction=0.02). B vitamin supplementation had no effect on progression of aortic or coronary artery calcification overall or within subgroups. CONCLUSIONS: High-dose B vitamin supplementation significantly reduces progression of early-stage subclinical atherosclerosis (carotid artery intima media thickness) in well-nourished healthy B vitamin "replete" individuals at low risk for cardiovascular disease with a fasting tHcy >or=9.1 micromol/L.
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: Howard N Hodis; Wendy J Mack; Laurie LaBree; Peter R Mahrer; Alex Sevanian; Chao-ran Liu; Ci-hua Liu; Juliana Hwang; Robert H Selzer; Stanley P Azen Journal: Circulation Date: 2002-09-17 Impact factor: 29.690
Authors: Aaron R Folsom; Moïse Desvarieux; F Javier Nieto; Lori L Boland; Christie M Ballantyne; Lloyd E Chambless Journal: Atherosclerosis Date: 2003-07 Impact factor: 5.162
Authors: Rex L Jamison; Pamela Hartigan; James S Kaufman; David S Goldfarb; Stuart R Warren; Peter D Guarino; J Michael Gaziano Journal: JAMA Date: 2007-09-12 Impact factor: 56.272
Authors: Tamas Alexy; Eszter Pais; Rosalinda B Wenby; Wendy J Mack; Howard N Hodis; Naoko Kono; Jun Wang; Oguz K Baskurt; Timothy C Fisher; Herbert J Meiselman Journal: Atherosclerosis Date: 2015-01-21 Impact factor: 5.162
Authors: Erin Foran Wolff; Yunxiao He; Dennis M Black; Eliot A Brinton; Mathew J Budoff; Marcelle I Cedars; Howard N Hodis; Rogerio A Lobo; Joann E Manson; George R Merriam; Virginia M Miller; Fredrick Naftolin; Lubna Pal; Nanette Santoro; Heping Zhang; S Mitchell Harman; Hugh S Taylor Journal: Fertil Steril Date: 2013-01-08 Impact factor: 7.329
Authors: Alberto Mazza; Stefano Cuppini; Laura Schiavon; Marco Zuin; Roberta Ravenni; Giulia Balbi; Domenico Montemurro; Giuseppe Opocher; Maria Rosa Pelizzo; Patrick M Colletti; Domenico Rubello Journal: Endocrine Date: 2013-10-03 Impact factor: 3.633
Authors: Keiko Kurita; Victor W Henderson; Margaret Gatz; Jan St John; Howard N Hodis; Roksana Karim; Wendy J Mack Journal: Fertil Steril Date: 2016-05-14 Impact factor: 7.329